Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elotuzumab - AbbVie/Bristol-Myers Squibb

Drug Profile

Elotuzumab - AbbVie/Bristol-Myers Squibb

Alternative Names: BMS-901608; Empliciti; HuLuc63; PDL063

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD319 antigen modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 20 Sep 2021 Biomarkers information updated
  • 23 Aug 2021 Bristol-Myers Squibb in a collaboration with Big Ten Cancer Research Consortium withdraw a phase II Immuno-POWER trial in Multiple myeloma (Combination therapy, Second-line therapy or greater, Maintenance therapy) before enrolment due to pulled funding support from funder (NCT04584307)
  • 30 Jun 2021 University of Chicago, Bristol-Myers Squibb and Amgen suspends a phase II trial for Multiple myeloma (Combination therapy, First-line therapy, Newly diagnosed) in USA (IV) (NCT02969837)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top